Pronova BioPharma ASA

Pronova BioPharma ASA (OSL:PRON) 5 November 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") today announces that its subsidiary Pronova BioPharma Norge AS has entered into a strategic supply agreement with Defiante Farmacêutica SA, a subsidiary of the Italian sigma-tau group, for the exclusive supply of the active pharmaceutical ingredient (API) for a fixed dose combination product with Omacor and simvastatin in Spain, France and Portugal, with a possibility to add other countries upon prior written agreement.

Pronova BioPharma ASA (OSL:PRON) 4 November, 2008, Lysaker, Norway: Primary insider Solveig Hellebust (Vice President HR and Communications ) has today through her wholly owned company Guldheim AS sold 25500 shares in Pronova BioPharma ASA at an average price of NOK 19.92 per share. After this transaction Mrs. Solveig Hellebust (and related parties) hold 776000 shares in the company.

Pronova BioPharma ASA (OSL:PRON) Pronova BioPharma posted strong third quarter results, driven by robust end-user demand and consistent performance at the Sandefjord plant. In-sourcing of intermediaries has facilitated the increase of the production forecast for 2009 to 1 400-1 500 tonnes. Positive results for the GISSI-heart failure trial were published at the European Society of Cardiology in August. Both primary endpoints were met.

Pronova BioPharma ASA (OSL:PRON) 4 November 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) announced today that the board of directors has appointed Per-Oluf Olsen as chief executive officer to succeed Tomas Settevik, who has informed the board that he wishes to stand down from his position as CEO.

Pronova BioPharma ASA (OSL:PRON) 23 October, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) will publish the group's third quarter results on Tuesday 4 November 2008.

Pronova BioPharma ASA (OSL:PRON) 16 September 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) will give a presentation at the UBS Global Life Sciences Conference in New York 23 September. The presentation will be available as webcast.

Pronova BioPharma ASA (OSL:PRON) 31 August, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") announces that the Phase III outcome trial GISSI-Heart Failure demonstrated that Omacor® reduced mortality and morbidity in patients with congestive heart failure (CHF).Both primary endpoints were met in the 7000 patient trial. The results were presented today at the European Society of Cardiology (ESC) Hot Line session in Munich, Germany. The findings were also published in The Lancet.

Pronova BioPharma ASA (OSL:PRON) 25 August, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) will host a webcast on Monday 1 September where top-line data from the GISSI-HF study will be presented.

Pronova BioPharma ASA (OSL:PRON) 22 August, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") today announces that it has entered into a sourcing agreement with an undisclosed third party manufacturer for the supply of intermediaries for the manufacture of Active Pharmaceutical Ingredients (APIs). The sourcing agreement will enable increased manufactured volumes of APIs in excess of earlier communicated volumes for 2009.

Pronova BioPharma ASA (OSL:PRON) 19 August, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") announces that the District Court of Rome, Italy, has decided not to uphold Pronova BioPharma's motion for a preliminary injunction against Chiesi Farmaceutici SpA ("Chiesi Farmaceutici"). Written arguments of the court's ruling have not yet been made available, and consequently the company is not in a position to comment on the contents of the ruling. The company believes the ruling will have no commercial impact given the continued strong growth in end-user sales and excess demand for the Active Pharmaceutical Ingredient on a global basis.